Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074920 | 0.88 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HTTL3MBTL1EPHX2 | |
| SCHEMBL24669800 | 0.81 | RAB9A (0.51) | ALDH1A1SMN1; SMN2HTTMAPTNPSR1 | |
| SCHEMBL6971648 | 0.79 | HTT (0.64) | ALDH1A1SMN1; SMN2HTTL3MBTL1EPHX2 | |
| SCHEMBL4730942 | 0.79 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HTTL3MBTL1EPHX2 | |
| SCHEMBL2625560 | 0.79 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2HTTL3MBTL1EPHX2 | |
| SCHEMBL25789181 | 0.79 | L3MBTL1 (0.50) | ALDH1A1SMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL21395217 | 0.79 | HIF1A (0.47) | ALDH1A1SMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL19851616 | 0.78 | SMN1; SMN2 (0.67) | ALDH1A1SMN1; SMN2HTTL3MBTL1EPHX2 | |
| SCHEMBL3937642 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2HTTL3MBTL1EPHX2 | |
| SCHEMBL4281439 | 0.78 | POLB (0.58) | ALDH1A1SMN1; SMN2HTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113840820-B | Phthalazinone compounds and uses thereof | ST制药株式会社 | 2024-05-03 | — | — | CN | claimed |
| CN-113840820-B | Phthalazinone compounds and uses thereof | ST制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ALDH1A1 993/4885SMN1; SMN2 2016/4885HTT 420/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALDH1A1 656/4885SMN1; SMN2 13/4885HTT 6/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ALDH1A1 1067/4885SMN1; SMN2 1917/4885HTT 365/4885 |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 2350/4885SMN1; SMN2 2473/4885HTT 432/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | ALDH1A1 4754/4885SMN1; SMN2 3143/4885HTT 1802/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ALDH1A1 656/4885SMN1; SMN2 13/4885HTT 6/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | ALDH1A1 4414/4885SMN1; SMN2 3489/4885HTT 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.